title: hsa-miR-191 is a candidate oncogene target for hepatocellular carcinoma therapy.
authors.affiliation: Rosetta Genomics Ltd., Rehovot, Israel.
authors.forename: Eran
authors.initials: E
authors.lastname: Elyakim
authors.forename: Einat
authors.initials: E
authors.lastname: Sitbon
authors.forename: Alexander
authors.initials: A
authors.lastname: Faerman
authors.forename: Sarit
authors.initials: S
authors.lastname: Tabak
authors.forename: Eve
authors.initials: E
authors.lastname: Montia
authors.forename: Liron
authors.initials: L
authors.lastname: Belanis
authors.forename: Avital
authors.initials: A
authors.lastname: Dov
authors.forename: Eric G
authors.initials: EG
authors.lastname: Marcusson
authors.forename: C Frank
authors.initials: CF
authors.lastname: Bennett
authors.forename: Ayelet
authors.initials: A
authors.lastname: Chajut
authors.forename: Dalia
authors.initials: D
authors.lastname: Cohen
authors.forename: Noga
authors.initials: N
authors.lastname: Yerushalmi